These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 28294178)

  • 1. Phosphorylated eIF2α predicts disease-free survival in triple-negative breast cancer patients.
    Guo L; Chi Y; Xue J; Ma L; Shao Z; Wu J
    Sci Rep; 2017 Mar; 7():44674. PubMed ID: 28294178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PERK-Phosphorylated eIF2α Pathway Suppresses Tumor Metastasis Through Downregulating Expression of Programmed Death Ligand 1 and CXCL5 in Triple-Negative Breast Cancer.
    Zou W; Bai Y; Wang X; Cheng K; Sun H; Zhang G; Wang X; Yang Z
    Cancer Biother Radiopharm; 2017 Oct; 32(8):282-287. PubMed ID: 29053414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Expression of CCR7 Predicts Lymph Node Metastasis and Good Prognosis in Triple Negative Breast Cancer.
    Li X; Sun S; Li N; Gao J; Yu J; Zhao J; Li M; Zhao Z
    Cell Physiol Biochem; 2017; 43(2):531-539. PubMed ID: 28930757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated expression of HABP1 is a novel prognostic indicator in triple-negative breast cancers.
    Wang J; Song Y; Liu T; Shi Q; Zhong Z; Wei W; Huang S; Pang D
    Tumour Biol; 2015 Jun; 36(6):4793-9. PubMed ID: 25794640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic role of SIRT1 associated with tumor invasion, lymph node metastasis, and poor disease-free survival in triple negative breast cancer.
    Chung SY; Jung YY; Park IA; Kim H; Chung YR; Kim JY; Park SY; Im SA; Lee KH; Moon HG; Noh DY; Han W; Lee C; Kim TY; Ryu HS
    Clin Exp Metastasis; 2016 Feb; 33(2):179-85. PubMed ID: 26585892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attenuation of malignant phenotypes of breast cancer cells through eIF2α-mediated downregulation of Rac1 signaling.
    Hamamura K; Minami K; Tanjung N; Wan Q; Koizumi M; Matsuura N; Na S; Yokota H
    Int J Oncol; 2014 Jun; 44(6):1980-8. PubMed ID: 24691491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options.
    Gasparini P; Fassan M; Cascione L; Guler G; Balci S; Irkkan C; Paisie C; Lovat F; Morrison C; Zhang J; Scarpa A; Croce CM; Shapiro CL; Huebner K
    PLoS One; 2014; 9(2):e88525. PubMed ID: 24505496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel genes associated with lymph node metastasis in triple negative breast cancer.
    Mathe A; Wong-Brown M; Morten B; Forbes JF; Braye SG; Avery-Kiejda KA; Scott RJ
    Sci Rep; 2015 Nov; 5():15832. PubMed ID: 26537449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulator of G protein signaling 20 correlates with clinicopathological features and prognosis in triple-negative breast cancer.
    Li Q; Jin W; Cai Y; Yang F; Chen E; Ye D; Wang Q; Guan X
    Biochem Biophys Res Commun; 2017 Apr; 485(3):693-697. PubMed ID: 28237701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A CLDN1-negative phenotype predicts poor prognosis in triple-negative breast cancer.
    Ma F; Ding X; Fan Y; Ying J; Zheng S; Lu N; Xu B
    PLoS One; 2014; 9(11):e112765. PubMed ID: 25393310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer.
    Jin MS; Hyun CL; Park IA; Kim JY; Chung YR; Im SA; Lee KH; Moon HG; Ryu HS
    Tumour Biol; 2016 Apr; 37(4):4743-53. PubMed ID: 26515337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The lymph node ratio as an independent prognostic factor for node-positive triple-negative breast cancer.
    He M; Zhang JX; Jiang YZ; Chen YL; Yang HY; Tang LC; Shao ZM; Di GH
    Oncotarget; 2017 Jul; 8(27):44870-44880. PubMed ID: 28496004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy.
    Honma N; Horii R; Ito Y; Saji S; Younes M; Iwase T; Akiyama F
    BMC Cancer; 2015 Oct; 15():698. PubMed ID: 26472348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients.
    Urru SAM; Gallus S; Bosetti C; Moi T; Medda R; Sollai E; Murgia A; Sanges F; Pira G; Manca A; Palmas D; Floris M; Asunis AM; Atzori F; Carru C; D'Incalci M; Ghiani M; Marras V; Onnis D; Santona MC; Sarobba G; Valle E; Canu L; Cossu S; Bulfone A; Rocca PC; De Miglio MR; Orrù S
    BMC Cancer; 2018 Jan; 18(1):56. PubMed ID: 29310602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
    Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
    Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD24 Overexpression Is Associated with Poor Prognosis in Luminal A and Triple-Negative Breast Cancer.
    Kwon MJ; Han J; Seo JH; Song K; Jeong HM; Choi JS; Kim YJ; Lee SH; Choi YL; Shin YK
    PLoS One; 2015; 10(10):e0139112. PubMed ID: 26444008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.
    Jézéquel P; Loussouarn D; Guérin-Charbonnel C; Campion L; Vanier A; Gouraud W; Lasla H; Guette C; Valo I; Verrièle V; Campone M
    Breast Cancer Res; 2015 Mar; 17():43. PubMed ID: 25887482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Gαh-PLCδ1 signaling axis drives metastatic progression in triple-negative breast cancer.
    Huang SP; Liu PY; Kuo CJ; Chen CL; Lee WJ; Tsai YH; Lin YF
    J Hematol Oncol; 2017 Jun; 10(1):114. PubMed ID: 28576130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of miR-34 rs4938723 T > C polymorphism in triple negative breast cancer patients.
    Tsiakou A; Zagouri F; Zografos E; Samelis G; Gazouli M; Kalapanida D; Giannos A; Marinopoulos S; Dimitrakakis K; Lazaris C A; Rigopoulos D; Zografos G
    Clin Biochem; 2019 Jun; 68():9-14. PubMed ID: 30935968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical relevance of the deregulated kallikrein-related peptidase 8 mRNA expression in breast cancer: a novel independent indicator of disease-free survival.
    Michaelidou K; Ardavanis A; Scorilas A
    Breast Cancer Res Treat; 2015 Jul; 152(2):323-36. PubMed ID: 26099606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.